Icalziss (Calcium Chloride Dihydrate)

After injection, calcium chloride dihydrate dissociates into calcium ions, raising extracellular calcium concentration. This increase enhances myocardial contractility, stabilises vascular smooth‑muscle tone, and provides essential cofactors for the coagulation cascade, thereby supporting heart function, blood pressure, and clot formation.

The dose of Icalziss is determined by the prescribing clinician based on the patient’s serum calcium level, clinical condition, and the specific procedure being performed. Healthcare professionals calculate the appropriate amount and rate of administration for each individual case.

Safety data for calcium chloride dihydrate in pregnancy and lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Icalziss, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and necessary import documentation.

Icalziss provides calcium chloride dihydrate, which delivers calcium ions rapidly and is especially useful for urgent correction of hypocalcemia or citrate anticoagulation reversal. Compared with calcium gluconate, calcium chloride contains a higher elemental calcium concentration, allowing smaller volumes for the same effect, but it may be more irritating to veins.

Icalziss should be stored at 2‑8 °C, protected from light, and must not be frozen. Keep the vial in its original packaging, avoid shaking the solution, and inspect for particulate matter before use. Follow standard aseptic techniques during preparation and administration.

Icalziss is administered intravenously by a qualified healthcare professional. The solution is typically diluted in compatible IV fluids and infused at a controlled rate, depending on the clinical indication and patient response. Administration should follow institutional protocols and monitor the patient for signs of calcium imbalance.

Serious risks include severe hypercalcemia, which can cause cardiac arrhythmias, cardiac arrest, or tissue necrosis if the solution extravasates. Rapid infusion may also lead to hypotension or pulmonary edema. Immediate medical attention is required if any severe adverse reaction is suspected.

Icalziss should be avoided in patients with known hypercalcemia, severe renal impairment, uncontrolled cardiac arrhythmias, or those who have had a severe allergic reaction to calcium chloride. Contraindications must be evaluated by the prescribing clinician before administration.